Open-label, Phase 1 Trial to Evaluate the Safety and Pharmacokinetic Parameters of a 2-day Pulse of Intravenous (IV) AC480 (AC480IV) Administered as Monotherapy and in Combination With Docetaxel in Patients With Advanced Solid Tumors.

Trial Profile

Open-label, Phase 1 Trial to Evaluate the Safety and Pharmacokinetic Parameters of a 2-day Pulse of Intravenous (IV) AC480 (AC480IV) Administered as Monotherapy and in Combination With Docetaxel in Patients With Advanced Solid Tumors.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs BMS 599626 (Primary) ; Docetaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Ambit Biosciences Corporation
  • Most Recent Events

    • 22 Jun 2015 Status changed from active, no longer recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 23 Jan 2013 Planned end date changed from 1 Mar 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 16 Apr 2012 Planned end date changed from 1 Apr 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top